Maya, LLC v. Cytodyn of New Mexico, Inc. (In Re Cytodyn of New Mexico, Inc.)

374 B.R. 733, 2007 Bankr. LEXIS 2422, 48 Bankr. Ct. Dec. (CRR) 174, 2007 WL 2545747
CourtUnited States Bankruptcy Court, C.D. California
DecidedJuly 20, 2007
DocketBankruptcy No. 07-11008-S11, Adversary No. 07-01325-TD
StatusPublished
Cited by3 cases

This text of 374 B.R. 733 (Maya, LLC v. Cytodyn of New Mexico, Inc. (In Re Cytodyn of New Mexico, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maya, LLC v. Cytodyn of New Mexico, Inc. (In Re Cytodyn of New Mexico, Inc.), 374 B.R. 733, 2007 Bankr. LEXIS 2422, 48 Bankr. Ct. Dec. (CRR) 174, 2007 WL 2545747 (Cal. 2007).

Opinion

MEMORANDUM OF DECISION

THOMAS B. DONOVAN, Bankruptcy Judge.

INTRODUCTION

This lawsuit is present in this court on Allen D. Allen’s (Allen or defendant) request for removal from the Los Angeles Superior Court. This decision deals with two motions. First, Maya, LLC (Maya or plaintiff), moves to remand the lawsuit back to the Los Angeles Superior Court, where Maya originally filed its complaint on September 30, 2005. In the second motion, Allen moves to transfer this adversary to the New Mexico bankruptcy court, where Cytodyn of New Mexico, Inc. (Cyto-dyn or Debtor), another defendant, filed for chapter 11 bankruptcy on April 27, 2007.

Upon consideration of the evidence and the briefs before me, the following are my findings of fact and conclusions of law. I conclude that Maya’s motion to remand should be granted, and Allen’s motion to transfer should be denied.

Maya’s pending complaint is based on allegations of misrepresentation/fraud, violation of securities laws, interference with contracts/economic interests, and breach of *736 contract. Maya asserts the following as a result of its investigation and discovery efforts, though no factual issues have been tried or decided by the superior court with respect to Maya’s complaint.

In the 1990’s, Allen obtained patents for a class of antibodies that supposedly could be used to treat HIV. He called the drug “Cytolin” and incorporated a business, Cy-todyn, to market its research and development to investors. Cytodyn had three employees: Allen himself, Allen’s daughter, Corinne D. Allen, and a third individual who is not a party to the present litigation.

Allen’s new corporation licensed the rights to the drug to a California corporation which in turn licensed them to Amerimmune Pharmaceuticals, Inc. (“Am-erimmune”), another party to the current proceeding. Amerimmune, Cytodyn, and Allen then pitched their drug to investors. Rex Lewis (“Lewis”), whose investment company is Maya, was one of those solicited. In the course of persuading Maya to invest in Cytolin, Maya alleges, Allen told a myriad of lies, including among others the following: that he was a doctor with a PhD, when, Maya asserts, he had never graduated from college; that the drug had been legally tested on 300 patients, when, Maya asserts, the drug that was tested had not been produced for use in humans and had been tested without FDA approval; 1 that the test showed the drug had been effective, and that there were no side effects, when, Maya asserts, there was no scientifically based evaluation of the drug.

Maya invested over $2 million in Am-erimmune. However, the drug went nowhere. Amerimmune went out of business. Lewis attempted to save his investment by becoming President and CEO of Amerimmune, but this was to no avail.

In February 2003, Allen caused Cytodyn to sue both Amerimmune and Lewis as an individual, in his capacity as an Amerim-mune board member. This suit was filed in the Los Angeles Superior Court. Maya alleges that Allen’s purpose in filing it was to intentionally expedite Amerimmune’s failure, clearing the way for new victims of Allen’s alleged scheme. The state court granted summary judgment against Cyto-dyn in November 2004. The state court also awarded attorneys’ fees to Maya based upon a finding of bad faith filing on the part of Cytodyn.

In the meantime, Lewis had filed a cross-complaint to Allen’s complaint. The parties subsequently signed a settlement agreement to the effect that Lewis would dismiss his cross-complaint and re-file his claims in Maya’s name. In the settlement, the parties agreed that Maya’s new action would be filed in the Los Angeles Superior Court, “where Allen D. Allen resides.” They also agreed to “cooperate in good faith in an effort to obtain the earliest practicable trial date.”

Maya’s new fraud action was filed on September 30, 2005. Maya’s claims included various common law fraud and securities fraud claims, as well as derivative claims asserted on behalf of Amerimmune.

Allen, however, did not cooperate in good faith to obtain an early trial date. The trial was initially set for February 5, 2007. Allen moved ex parte for a continuance. Allen’s motion was granted, but the court warned that there would be no further continuances. A new trial date was set for May 7, 2007. As that date approached, Allen asked Maya to agree to *737 another continuance, but Maya refused. On April 26, not much more than a week before the scheduled trial date, Cytodyn filed for bankruptcy in New Mexico. Allen removed Maya’s action to this court the next day, pursuant to F.R.B.P. 9027(a). 2

Although Cytodyn was incorporated in New Mexico, where it has filed for bankruptcy, Maya asserts that Cytodyn has few other connections with that state. Allen, president and C.E.O., with total voting control of the company, is a California citizen, San Francisco born. The other two Cytodyn employees lived in California at least during the time that the events giving rise to the Maya lawsuit took place. All Cytodyn board meetings were held in Los Angeles. Substantial promotional activities with respect to Cytolin took place in Los Angeles. Various agreements relating to investment in the drug and its licensing were executed in Los Angeles. Allen allegedly made fraudulent statements to Maya in California. Indeed, it was Allen himself who, in the Los Angeles Superior Court, initiated the suit against Amerimmune that led to the present Maya action.

Maya’s complaint and the resulting litigation has been removed to this court. Allen seeks a transfer to New Mexico bankruptcy court; Maya seeks abstention and remand. I conclude that Allen’s motion to transfer should be denied and Maya’s motion to remand should be granted.

ABSTENTION AND REMAND

Abstention

Maya argues that the court should abstain from hearing the action, citing 28 U.S.C. § 1334(c)(1) and (2). Section 1334(c)(2) provides for mandatory abstention:

“Upon timely motion of a party in a proceeding based upon a State law claim or State law cause of action, related to a case under title 11 but not arising under title 11 or arising in a case under title 11, with respect to which an action could not have been commenced in a court of the United States absent jurisdiction under this section, the district court shall abstain from hearing such proceeding if an action is commenced, and can be timely adjudicated, in a State forum of appropriate jurisdiction.”

Section 1334(c)(1) provides for discretionary abstention:

“... nothing in this section prevents a district court in the interest of justice, or in the interest of comity with State courts or respect for State law, from abstaining from hearing a particular proceeding arising under title 11 or arising in or related to a case under title 11.”

11 U.S.C. § 305

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
374 B.R. 733, 2007 Bankr. LEXIS 2422, 48 Bankr. Ct. Dec. (CRR) 174, 2007 WL 2545747, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maya-llc-v-cytodyn-of-new-mexico-inc-in-re-cytodyn-of-new-mexico-cacb-2007.